Skip to main content
SpringerLink
Log in

Polypill Strategy in Secondary Cardiovascular Prevention

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The polypill strategy, originally developed to improve medication adherence, has demonstrated efficacy in improving baseline systolic blood pressures and cholesterol levels in multiple clinical trials. However, the long-term clinical impact of improved major cardiovascular events (MACE) outcomes by the polypill remains uncertain.

Recent Findings

Recent trials with long-term follow-up, which included minority groups and people with low socioeconomic status, have shown non-inferiority with no difference in adverse effects rates for the secondary prevention of MACE.

Summary

Although the polypill strategy was initially introduced to improve adherence to guideline-directed medical therapy (GDMT) for cardiovascular complications, the strategy has surpassed standard medical treatment for secondary prevention of MACE outcomes. Studies also showed improved medication compliance in underserved populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

No datasets were generated or analyzed during the current study.

References

Papers of particular interest, published recently, have been highlighted as: •  Of importance

  1. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Savarese G, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87.

    Article  PubMed  Google Scholar 

  3. Roth GA, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Mensah GA, et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023;82(25):2350–473.

    Article  PubMed  Google Scholar 

  5. Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9–119.

    Article  PubMed  Google Scholar 

  6. Tsao CW, et al. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93–621.

    Article  PubMed  Google Scholar 

  7. Krumholz HM, Normand S-LT, Wang Y. Twenty-year trends in outcomes for older adults with acute myocardial infarction in the United States. JAMA Netw Open. 2019;2(3):e191938–e191938.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201(Suppl 1):S1-7.

    Article  PubMed  Google Scholar 

  9. Mukherjee D, et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109(6):745–9.

    Article  PubMed  Google Scholar 

  10. • Castellano JM, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387(11):967–977. First trial to significantly show reduction in event rates when compared to standard of care (indivial pharmacological intervention for CVD risk factors).

  11. Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet. 2017;389(10073):1055–65.

    Article  PubMed  Google Scholar 

  12. Cainzos-Achirica M, et al. Pathways forward in cardiovascular disease prevention one and a half years after publication of the 2013 ACC/AHA cardiovascular disease prevention guidelines. Mayo Clin Proc. 2015;90(9):1262–71.

    Article  PubMed  Google Scholar 

  13. Spring S, Food U, Administration D. Guidance for industry-diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US: US Food and Drug Administration. 2008.

  14. Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(38):3720–826.

    Article  CAS  PubMed  Google Scholar 

  15. Corrigendum to: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Euro Heart J. 2022;43(42):4468–4468.

  16. Yusuf S, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231–43.

    Article  PubMed  Google Scholar 

  17. Kelly MS, et al. Efficacy and safety of a polypill to reduce cardiovascular events: a review of clinical trials. J Cardiovasc Pharmacol. 2024;83(1):8–15.

    Article  CAS  PubMed  Google Scholar 

  18. Bahit MC, et al. Patient adherence to secondary prevention therapies after an acute coronary syndrome: a scoping review. Clin Ther. 2023;45(11):1119–26.

    Article  CAS  PubMed  Google Scholar 

  19. Akioyamen LE, et al. Association of neighborhood-level marginalization with health care use and clinical outcomes following hospital discharge in patients who underwent coronary catheterization for acute myocardial infarction in a single-payer health care system. Circ Cardiovasc Qual Outcomes. 2023;16(12): e010063.

    Article  PubMed  Google Scholar 

  20. Hayek A, et al. An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. Implement Sci. 2016;11(1):129.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J. 2006;27(14):1651–6.

    Article  PubMed  Google Scholar 

  22. Zeymer U, et al. Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR). Int J Cardiol. 2013;170(2):239–45.

    Article  PubMed  Google Scholar 

  23. • Roshandel G, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–683. Large randomized trial conducted in low- and middle-income countries for secondary prevention of cardiovascular events with a legnthy follow-up. First trial to compare objective MACE incident rates at 36 months.

  24. Charan J, Goyal JP, Saxena D. Effect of pollypill on cardiovascular parameters: systematic review and meta-analysis. J Cardiovasc Dis Res. 2013;4(2):92–7.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Yusuf S, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341–51.

    Article  CAS  PubMed  Google Scholar 

  26. Kim J-H, et al. Proactive cardiovascular risk management versus usual care in patients with and without diabetes mellitus: CRUCIAL trial subanalysis. Postgrad Med. 2012;124(4):41–53.

    Article  PubMed  Google Scholar 

  27. Suwaidi JA. Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings. Glob Cardiol Sci Pract. 2016;2016(2):e201613.

    PubMed  PubMed Central  Google Scholar 

  28. Selak V, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ: Br Med J. 2014;348:g3318.

  29. Patel A, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920–30.

    Article  PubMed  Google Scholar 

  30. Agnello F, et al. A review of polypills for the prevention of atherosclerotic cardiovascular disease. Am Heart J. 2023;266:74–85.

    Article  CAS  PubMed  Google Scholar 

  31. Thom S, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918–29.

    Article  CAS  PubMed  Google Scholar 

  32. Castellano JM, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071–82.

    Article  PubMed  Google Scholar 

  33. Lozano I. Cross-over analysis of the control of coronary risk factors and level of platelet inhibition with a polypill. Clinicaltrials.gov. 2023. NCT05030818.

  34. Pandey A. Polypill strategy for evidence-based management of patients with acute coronary syndrome undergoing percutaneous coronary intervention in an underserved patient population. November 30, 2023, NCT05514938: Clinicaltrials.gov.

  35. Greene SJ, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351–66.

    Article  PubMed  Google Scholar 

  36. Pandey A, Keshvani N, Wang TJ. Should polypills be used for heart failure with reduced ejection fraction? Circulation. 2022;146(4):276–8.

    Article  PubMed  Google Scholar 

  37. Heidenreich Paul A, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–421.

    Article  CAS  PubMed  Google Scholar 

  38. Ens TA, et al. South Asians’ cardiac medication adherence. Eur J Cardiovasc Nurs. 2014;13(4):357–68.

    Article  PubMed  Google Scholar 

  39. Setoguchi S, et al. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008;51(13):1247–54.

    Article  PubMed  Google Scholar 

  40. Nieuwlaat R, et al. Interventions for enhancing medication adherence. Cochrane Database of Syst Rev. 2014(11).

  41. Teo K, et al. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009;158(1):1-7.e1.

    Article  PubMed  Google Scholar 

  42. Sadeghi M. Fixed combination therapy for secondary prevention of major cardiovascular events. 2020. Clinicaltrials.gov. NCT03541109.

  43. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Muñoz D, et al. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med. 2019;381(12):1114–23.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227–337.

    Article  PubMed  Google Scholar 

  46. Smith SC, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation. 2011;124(22):2458–73.

    Article  PubMed  Google Scholar 

  47. Roshandel G, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA

    Alan De la Rosa

  2. Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, 79905, USA

    Kedzie Arrington

  3. Division of Cardiovascular Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA

    Rohan Desai

  4. Division of Nephrology Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA

    Prakrati C. Acharya

Authors
  1. Alan De la Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kedzie Arrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rohan Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prakrati C. Acharya
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AR, KA, and RD wrote the main manuscript text, and all authors reviewed the manuscript.

Corresponding author

Correspondence to Prakrati C. Acharya.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De la Rosa, A., Arrington, K., Desai, R. et al. Polypill Strategy in Secondary Cardiovascular Prevention. Curr Cardiol Rep (2024). https://doi.org/10.1007/s11886-024-02046-1

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11886-024-02046-1

Keywords

Search

Navigation